UMIN ID: UMIN000011693
Registered date:09/09/2013
Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate in patients with unresectable advanced or recurrent breast cancer
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Unresectable advanced or recurrent breast cancer |
| Date of first enrollment | 2013/09/05 |
| Target sample size | 50 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Eribulin mesylate administer day 1, day 8, tri-weekly interval. The trial treatment will be continued until there is progressive disease. we will evaluate the variation of eribulin pharmacokinetics at cycle1 day1. |
Outcome(s)
| Primary Outcome | -Pharmacokinetic analysis of eribulin -Correlation between effectiveness/toxicity and pharmacokinetics of eribulin |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 75years-old |
| Gender | Female |
| Include criteria | |
| Exclude criteria | a)Patients with brain metastases with symptoms b)Patients with the body cavity fluid marked (pleural effusion, ascites, pericardial effusion). However, it can be registered if good control due to the administration of adhesion agent. c)Patients with synchronous double cancer, not including lesions equivalent to carcinoma in situ or mucosal carcinoma considered healed with topical therapy d)Patients with complications is determined causing serious problems in the implementation of treatment - Patients with poor control diabetes - Patients with activity infection - Patients with pulmonary fibrosis or interstitial pneumonia on chest X-ray - Patient with protocol difficult-to-treat caused by the mental state or neuropsychiatric disorders - Patients with watery diarrhea chronic - Patients with ileus, significant bleeding tendency, and gastrointestinal bleeding - Patients with uncontrolled angina and myocardial infarction and heart disease merger severe cases with heart failure that developed within three months e)Pregnant or breast-feeding women, or women of child bearing potential who intend to become pregnant |
Related Information
| Primary Sponsor | National Cancer Center Hospital |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Japan Medical Association |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Kenji Tamura |
| Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo104-0045, Japan Japan |
| Telephone | 03-3542-2511 |
| ketamura@ncc.go.jp | |
| Affiliation | National Cancer Center Hospital Breast and Medical Oncology Division |
| scientific contact | |
| Name | Kenji Tamura |
| Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo104-0045, Japan Japan |
| Telephone | 03-3542-2511 |
| ketamura@ncc.go.jp | |
| Affiliation | National Cancer Center Hospital Breast and Medical Oncology Division |